Munoz-Garcia B - Search Results

1

Martin-Ventura JL, Munoz-Garcia B, Egido J, Blanco-Colio LM. Martin-Ventura JL, et al. Front Biosci. 2007 May 1;12:3656-67. doi: 10.2741/2342. Front Biosci. 2007. PMID: 17485329 Review.

2

TWEAK and Fn14. New players in the pathogenesis of atherosclerosis.

Blanco-Colio LM, Martín-Ventura JL, Munoz-Garcia B, Moreno JA, Meilhac O, Ortiz A, Egido J. Blanco-Colio LM, et al. Front Biosci. 2007 May 1;12:3648-55. doi: 10.2741/2341. Front Biosci. 2007. PMID: 17485328 Review.

3

Considering TWEAK as a target for therapy in renal and vascular injury.

Ortiz A, Sanz AB, Muñoz García B, Moreno JA, Sánchez Niño MD, Martín-Ventura JL, Egido J, Blanco-Colio LM. Ortiz A, et al. Among authors: munoz garcia b. Cytokine Growth Factor Rev. 2009 Jun;20(3):251-8. doi: 10.1016/j.cytogfr.2009.05.002. Epub 2009 May 30. Cytokine Growth Factor Rev. 2009. PMID: 19482507 Review.

4

[Vasoprotective effects of statins and angiotensin II blockers in atherothrombosis].

Egido J, Ruiz-Ortega M, Muñoz-García B, Martín-Ventura JL, Blanco-Colio LM. Egido J, et al. Nefrologia. 2005;25 Suppl 2:117-28. Nefrologia. 2005. PMID: 16050414 Free article. Review. Spanish.

5

3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors decrease Fas ligand expression and cytotoxicity in activated human T lymphocytes.

Blanco-Colio LM, Muñoz-García B, Martín-Ventura JL, Lorz C, Díaz C, Hernández G, Egido J. Blanco-Colio LM, et al. Circulation. 2003 Sep 23;108(12):1506-13. doi: 10.1161/01.CIR.0000089086.48617.2B. Epub 2003 Sep 2. Circulation. 2003. PMID: 12952848

6

NF-kappaB activation and Fas ligand overexpression in blood and plaques of patients with carotid atherosclerosis: potential implication in plaque instability.

Martín-Ventura JL, Blanco-Colio LM, Muñoz-García B, Gómez-Hernández A, Arribas A, Ortega L, Tuñón J, Egido J. Martín-Ventura JL, et al. Stroke. 2004 Feb;35(2):458-63. doi: 10.1161/01.STR.0000114876.51656.7A. Epub 2004 Jan 22. Stroke. 2004. PMID: 14739407

7

Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month.

Martín-Ventura JL, Blanco-Colio LM, Gómez-Hernández A, Muñoz-García B, Vega M, Serrano J, Ortega L, Hernández G, Tuñón J, Egido J. Martín-Ventura JL, et al. Stroke. 2005 Aug;36(8):1796-800. doi: 10.1161/01.STR.0000174289.34110.b0. Epub 2005 Jul 14. Stroke. 2005. PMID: 16020773 Clinical Trial.

8

Fn14 is upregulated in cytokine-stimulated vascular smooth muscle cells and is expressed in human carotid atherosclerotic plaques: modulation by atorvastatin.

Muñoz-García B, Martín-Ventura JL, Martínez E, Sánchez S, Hernández G, Ortega L, Ortiz A, Egido J, Blanco-Colio LM. Muñoz-García B, et al. Stroke. 2006 Aug;37(8):2044-53. doi: 10.1161/01.STR.0000230648.00027.00. Epub 2006 Jun 29. Stroke. 2006. PMID: 16809572

9

Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis.

Blanco-Colio LM, Martín-Ventura JL, Muñóz-García B, Orbe J, Páramo JA, Michel JB, Ortiz A, Meilhac O, Egido J. Blanco-Colio LM, et al. Arterioscler Thromb Vasc Biol. 2007 Apr;27(4):916-22. doi: 10.1161/01.ATV.0000258972.10109.ff. Epub 2007 Feb 1. Arterioscler Thromb Vasc Biol. 2007. PMID: 17272745 Free article.

10

Leukotriene B4 enhances the activity of nuclear factor-kappaB pathway through BLT1 and BLT2 receptors in atherosclerosis.

Sánchez-Galán E, Gómez-Hernández A, Vidal C, Martín-Ventura JL, Blanco-Colio LM, Muñoz-García B, Ortega L, Egido J, Tuñón J. Sánchez-Galán E, et al. Cardiovasc Res. 2009 Jan 1;81(1):216-25. doi: 10.1093/cvr/cvn277. Epub 2008 Oct 13. Cardiovasc Res. 2009. PMID: 18852255

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

24 results

Search Page

Filters